Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical timolol for conjunctival pyogenic granuloma
IRCT20160523028008N27Phase 3Completed
- Sponsor
- Hamadan University of Medical Sciences
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of timolol in Pyogenic granuloma of the conjunctiva (PG), sponsored by Hamadan University of Medical Sciences. Primary endpoints: Lesion improvement, Lesion recurrence and 1 more. Started Jan 2023; status: completed.
02
Drugs
timolol
03
Conditions
Pyogenic granuloma of the conjunctiva (PG)
Beyond the preview
Go deeper on IRCT20160523028008N27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20160523028008N27.